CURRENT
ISSUE
1583

Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication.1 Available vaccines and recommendations for specific patient populations for the 2019-2020 season are listed in Tables 2 and 3.

TIMING — In the US, influenza vaccine should be offered by the end of October and continue to be offered for as long as influenza is circulating in the community. In most adults, serum antibody levels peak about two weeks after vaccination.Continue reading

More from Issue 1583
Previous Issue: 1582      October 7, 2019
Coming Soon
Drugs for Type 2 Diabetes
Turmeric Supplements
Upadacitinib (Rinvoq) for Rheumatoid Arthritis
Darolutamide (Nubeqa) for Prostate Cancer
Search
Subscribe
Conversation
Follow us  facebook        Email Alerts
 Tweets
FROM
ISSUE
1583

An oral formulation of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Rybelsus – Novo Nordisk) has been approved by the FDA for once-daily treatment of type 2 diabetes in adults. Semaglutide, which has been available in a subcutaneously-injected formulation (Ozempic)1 since 2017, is the first GLP-1 receptor agonist to become available for oral administration; the 4 other GLP-1 receptor agonists currently available in the US are administered by subcutaneous (SC) injection.

Continue reading